Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.59), $0.08 better than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.